News
-
-
-
COMMUNIQUÉ DE PRESSE
MIRA Pharmaceuticals Initiates Multiple Ascending Dose (MAD) Phase 1 Study of Oral Ketamir-2 and Selects Chemotherapy-Induced Neuropathic Pain as Lead Phase 2a Indication
MIRA Pharmaceuticals advances Ketamir-2 into Phase 2a clinical evaluation for chemotherapy-induced peripheral neuropathy with potential for FDA Fast Track status -
-
-
COMMUNIQUÉ DE PRESSE
MIRA Pharmaceuticals Announces Oral Mira-55 Outperformed Injected Morphine in Normalizing Pain and Reducing Inflammation, Supporting Its Planned IND for Chronic Inflammatory Pain
MIRA Pharmaceuticals unveils groundbreaking preclinical data on pain relief & inflammation reduction with oral Mira-55, positioning itself in $70B non-opioid pain market -
-
-
COMMUNIQUÉ DE PRESSE
MIRA Pharmaceuticals Closes Acquisition of SKNY Pharmaceuticals, Expands Pipeline with SKNY-1 for Obesity and Nicotine Addiction
MIRA Pharmaceuticals completes acquisition of SKNY Pharmaceuticals, strengthening financial position. SKNY-1 for obesity and smoking cessation, Ketamir-2 for neuropathic pain, and MIRA-55 for inflammatory pain -
